Aspen Neuroscience seeks up to $155M in its Nasdaq IPO to fund a Phase III trial of its iPSC-derived cell therapy for ...
Researchers at Huazhong Agricultural University have developed AbOptimizer, a reinforcement-learning framework that proposes ...
LYNK Pharmaceutical's zemprocitinib sustained ACR20 response above 91% in Phase III rheumatoid arthritis trial. Discover the full long-term results and ...
Astellas secures an exclusive option to license Audax's DAX-044, a preclinical IL-12 cancer antibody, in a deal worth up to ...
Nxera exercises its option for exclusive rights to Idorsia's lucerastat for Fabry disease in Japan and Asia ex-China. Read ...
Novartis takes a $1.9B delgocitinib writedown after a Duchenne failure as remibrutinib nears FDA filing in MS. Read the full ...
Genmab's petosemtamab met its main goals in a Phase III head and neck cancer trial and is heading to regulators. Read what the results mean for patients.
Oruka's ORKA-001 hit 61% complete skin clearance in Phase IIb EVERLAST-B psoriasis trial. Phase III. Read the full results ...
Teva acquires worldwide rights to BXCL501 sublingual film from BioXcel: $57.5M upfront, up to $125M total. Read the full deal ...
Insilico's AI-designed pan-TEAD inhibitor ISM6331 posted a 40% objective response rate at 130 mg in early mesothelioma data.
Merck's sac-TMT met both primary endpoints in Phase III TroFuse-005 for advanced endometrial cancer and is heading to FDA ...
Rhode Island and Massachusetts life science groups sign MOU to plan a shared regional biobank for brain disease research.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results